Clara Hwang, MD

Articles

Dr. Hwang on the Addition of Radium-223 to Abiraterone Acetate and Prednisone in mCRPC

May 5th 2020

Clara Hwang, MD, discusses the phase 3 ERA-223 trial evaluating the addition of radium-223 dichloride to abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and bone metastases.

Dr. Hwang on the Utility of Docetaxel in mCSPC

April 24th 2020

Clara Hwang, MD, discusses the utility of docetaxel and abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr. Hwang on the Utility of Antiandrogens in Metastatic Prostate Cancer

April 14th 2020

Clara Hwang, MD, discusses the utility of antiandrogens in patients with metastatic prostate cancer.

Dr. Hwang on the Evolution of Treatment in Metastatic CSPC

February 7th 2020

Clara Hwang, MD, discusses the evolution of treatment for men with metastatic castration-sensitive prostate cancer.

Dr. Hwang on the State of Treatment in Metastatic Prostate Cancer

January 29th 2020

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the state of treatment in metastatic prostate cancer.

Dr. Hwang on Treatment Selection in Metastatic Castration-Sensitive Prostate Cancer

January 24th 2020

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses treatment selection in newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC).

Dr. Hwang on Choosing Agents for Prostate Cancer Treatment

January 8th 2020

Clara Hwang, MD, discusses factors that can be used to decide what agent to use in the frontline setting for patients with metastatic castration-sensitive or castration-resistant prostate cancer.